On September 10 an international team of experts from the UCL School of Pharmacy, LSE Health and Hacettepe University will release a research paper on the economic and social impacts of chronic disease in Turkey. Chronic non communicable diseases annually cost Turkey $US 60 billion in total value of forgone life and ability. This number rises to $US 80 billion when neuro-psychiatric conditions such as dementias are included. This represents a lost welfare value of 8 to 10 percent of GDP.
Over the recent past, Turkey has made remarkable progress in addressing major health challenges. Since 1970 Turkey’s population has more than doubled, life expectancy has increased by 25 years and infant mortality has fallen from 145 per 1000 live births to 10 per 1000 live births. However, Turkey faces significant new health challenges from the growing economic and social burden resulting from the increased diagnosed prevalence of chronic, non-communicable diseases. Effective intervention in this field will permit the Turkish population to continue enjoying swift health improvement in the next stage of the country’s progress, and to build its growing reputation for leadership in the health sector.
Hacettepe University in association with the Partnership to Fight Chronic Disease (PFCD) will officially release the study “Transforming Health in Turkey: 21st Century Opportunities”. This paper was researched, developed and written by an international team of experts from the UCL School of Pharmacy, LSE Health and Hacettepe University.
The release of the paper will take place at Rixos Grand Ankara Hotel (Atatürk Bulvarı, 183 Kavaklıdere 06680, Ankara) on September 10, 2012 at 11 a.m.
Speakers will include: